AzTrials
AzTrials

Schizophrenia DisordersMEGPSYNCT06978881

Magnetoencephalography in Psychosis Program

An observational study of Schizophrenia Disorders and Psychosis, run by Douglas Mental Health University Institute at 1 site in Canada.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This research involves the examination of speech, thinking patterns and symptoms and recordings from brain's activity in patients with schizophrenia. The reserchers are investigating if the electrical waves (recorded indirectly using the resulting magnetic field around our head) are disrupted in psychosis, especially… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Schizophrenia Disorders, Psychosis
How many people
50 participants
Where
1 siteCanada
Study dates
8 May 2024to Nov 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Patients will be recruited from 3 institutions; 1. Douglas Mental Health University Institute 2. Lakeshore General Hospital and 3. McGill University Health Centre. Initial contact and information about this study will be communicated by clinicians who are members of the patient's mental health care team at these locations. Healthy Control participants will be recruited from the Greater Montreal Area using online study advertisements and research study posters placed on bulletin boards at the three Mental Health Institutions

Who may be able to join

  • Clinical diagnosis of schizophrenia as per DSM-5 criteria.
  • Aged between 18 and 50 years.
  • In a stable phase of the illness (no change in Global Functioning > 10 units within 1 month before the MEG scan assessed using the Global Assessment of Functioning Scale).
  • Healthy volunteers aged between 18 and 50 years.
  • Matched to patients for age (within 2 years), sex, and parental occupational status (rated by NS-SEC).

Who cannot join

  • Inability to speak English or French.
  • History of head trauma, major neurological disorders (e.g., epilepsy), somatic disorders with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities.
  • Diagnosis of substance use disorder (current or within the last year) as per DSM-5.
  • Unsuitable for MRI due to safety concerns (e.g., metal in the body, pregnancy, tinnitus).
  • Healthy Controls
  • Inability to speak English or French.
Show all 10Show fewer
  • History of head trauma, major neurological disorders (e.g., epilepsy), somatic disorders with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities.
  • Diagnosis of substance use disorder (current or within the last year) as per DSM-5.
  • Personal or family history of psychotic disorder.
  • Unsuitable for MRI due to safety concerns (e.g., metal in the body, pregnancy, tinnitus).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Canada1 site
  • Douglas Mental Health University Institute

    Montreal, Quebec, H4H 1R3

Other trials in Canada

About this study

Official title: Temporal Regularity of Neural Activity and Its Relationship to Psychotic Symptoms

This research involves the examination of speech, thinking patterns and symptoms and recordings from brain's activity in patients with schizophrenia. The reserchers are investigating if the electrical waves (recorded indirectly using the resulting magnetic field around our head) are disrupted in psychosis, especially in the language related problems seen in this disorder. To examine language, participants will be asked to complete a speech tasks using the DISCOURSE speech elicitation script in which they will be requested to share their thoughts. For this purpose, the participants will be shown some pictures and asked to describe what they see, discuss a significant event from their life and tell a story in their own words. The description of the pictures and other responses to the tasks will be audio-recorded for later transcription into a written format.

The researches will examine the brain regions using Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI). MEG and MRI are both non-invasive functional brain imaging technologies. MRI collects structural information and creates images of the brain while MEG collects magnetic activity from neurons, visualized as brain waves. The MRI machine uses a large magnet to help create images while MEG captures the fluctuations in the small magnetic fields resulting from brain's activity. Participants will also undergo a clinical and neurocognitive assessments.

This project design involves 50 individuals who will take part in the study; 25 affected and 25 healthy volunteers aged 18 to 50 years.

Read the detailed description

Schizophrenia is a common and severe mental illness affecting millions of people worldwide. With a lifetime prevalence of about 1%, it is estimated to generate annual costs of $10 billion in Canada alone, with cognitive and functional impairments as major contributors. One of the main and most debilitating symptoms of schizophrenia is related to the disorganization and impoverishment of speech, also known as Formal Thought Disorder (FTD). The presence of linguistic disorganization and impoverishment seen in FTD is recognized as an early marker of disease; it can be present in otherwise healthy adolescents or those in prodromal or at-risk stages and predict the onset of a first psychotic episode. In the context of a well-established diagnosis, it serves as an indicator of decompensation severity and disease prognosis and is associated with occupational and social functioning. Yet, FTD remains poorly understood and largely understudied, hindered by difficulties in clinical assessment. The recent emergence of objective computer-based analysis of speech (Natural Language Processing) to generate markers of disruptions in syntax, meaning and parts-of-speech has revived the field, promising to offer novel insights into how communication becomes disrupted in the presence of psychosis.

Pathophysiological enquiries into schizophrenia to date suggest that it is a disorder of dysconnectivity in both spatial and temporal dimensions, with both being related to neurochemical aberrations such as subcortical dopamine excess. In other words, the relationship among various parts of the brain constituting networks (a spatial dimension) appears to be notably affected. This occurs in conjunction with a disruption in the moment-to-moment physiological continuity, or temporal irregularity, in neuronal activity. The spatial disconnect is well captured using functional magnetic resonance imaging (fMRI) while the temporal irregularity can be studied using oscillatory patterns in the electroencephalography (EEG). In more recent times, the capability to concurrently study both spatial and temporal dysconnectivity has emerged from the use of magnetoencephalography (MEG), while non-invasive proxy measurements of dopamine function are feasible from short anatomical scans.

In the era of precision medicine, individual characterisation of the disease can support both diagnosis and treatment response. Magnetoencephalography (MEG) has shown to be a powerful tool to study the underpinnings of verbal production using task-free and task-based paradigms. Recent data published by the Baillet lab have shed light on novel approaches to spectral brain mapping and speech impairment quantification to characterize the functional neural pathology contributing to speech impairment in patients with Parkinson's disease. A previous study has demonstrated the feasibility of identifying individual specific patterns, termed 'brain fingerprints', in healthy participants using MEG for as short as 30 seconds. Recovering specific neural patterns from brief non-invasive recordings is very promising for the study of psychosis, however, no prior studies have investigated the spectral and connectome fingerprint of patients with schizophrenia. In addition to characterizing the speech abnormalities prevalent in patients with schizophrenia, identifying individual markers of temporal connectivity will enable us to understand the mechanism behind disorganised language in psychosis.

It has been shown that healthy individuals exposed to asynchronous audiovisual stimuli (i.e., out of the expected similar timing) undergo a rapid neural tuning or resetting (temporal recalibration). This relevant physiological mechanism is linked to our response to dynamic changing environments, such as speech comprehension. Previous research has shown that multisensory integration is impaired in schizophrenia; however, no previous studies have tried to dissect the temporal and spatial oscillatory mechanisms through which this phenomenon occurs and whether the degree of desynchrony correlates to psychotic symptoms.

Previous studies have also identified synchronized neural oscillatory activity as one of the physiological mechanisms underlying the hierarchical and integrative process of language production in healthy state. In line with these findings, research studies have suggested that beta oscillatory activity are involved in language production. Brain oscillations in the alpha and beta frequency ranges are considered as indices of sensorimotor integration in speech perception and production. Previous findings in healthy participants with high schizotypy (a trait that is related to the construct of schizophrenia) and patients with schizophrenia have led to the hypothesis that beta oscillatory dysfunction are key contributors to the mechanism of symptom formation and persistence in schizophrenia. Beta oscillations are thought to play a key role in the maintenance of prior context that is essential for coherent motor action and speech production; when this is disrupted, speech may contain words that are 'out-of-context' i.e., lower predictability for a given context . In particular, beta-band oscillations appear to 'carry the predictions' about the ongoing context, thus mediating top-down interactions between motor and frontotemporal language system during auditory listening tasks , by suppressing cortical responses to predicted sensory input. Inappropriate language area activity (resulting in disorganised speech) can thus be expected to arise from beta band deficits in schizophrenia.

Two key proofs are needed to further advance the hypothesis of beta deficits in schizophrenia: (1) Demonstrating beta-oscillatory deficits in patients with an established diagnosis of schizophrenia, especially in the language network that is thought to underlie FTD, and (2) Relating the specific patterns of temporal connectivity (spectral connectome) and irregularity (beta-oscillatory deficits) in the brain of affected individuals to objective measures of thought disorder using computerised analysis of speech.

PURPOSE The primary purpose of this study is to demonstrate that deficits in beta-band power in the motor cortex (elicited via a simple motor task of responding to a tone) and spectral similarity of language network (at rest) occur in schizophrenia. In patients with schizophrenia, the investigators expect these deficits to correlate with the degree of disorganisation measured as semantic predictability/coherence (by analysing recorded speech analysis).

HYPOTHESES Hypothesis 1: Beta-band oscillatory power (rebound from baseline after task execution) during a simple motor task in response to audiovisual stimuli is affected in schizophrenia.

Hypothesis 2: Across both patients and controls, the beta-rebound after motor task will correlate with coherent speech production (context-based semantic coherence or predictability) measured offline.

Hypothesis 3: Among patients with schizophrenia, the spectral maps for beta oscillatory frequency will show the greatest deviation from healthy controls in the frontotemporal language network.

The researchers also aim to explore if resting-state MEG connectomes across multiple frequency bands in schizophrenia display deviations from unaffected healthy subjects, if multisensory integration through rapid temporal recalibration is schizophrenia differs from that of healthy individuals, and if cortical structure (by measuring cortical thickness, and folding pattern) and subcortical profile of dopamine turnover (by measuring neuromelanin) relate to the MEG spectral deviations. The correlations obtained through the above-mentioned exploratory hypothesis will serve to estimate likely effect sizes to plan future larger studies.

Keywords
Magnetoencephalography, MEG, temporal regularity, Language disorders, neural activity, natural language processing, disorganization, impoverishment, formal thought disorder
Medical subject headings
Schizophrenia, Psychotic Disorders, Language Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06978881
Study groupRoleWhat they receive
Healthy controls25 healthy volunteers; (1)English or French speeking, (2) Aged 18 to 50 years (group-matched with the patients for age (within 2 years), sex and parental occupational status, rated according to the National Statistics Socio-Economic Classification), (3) No personal or family history of psychotic disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria, (4) No history of head trauma, major neurological disorder (e.g., epilepsy) or somatic disorder with neurological complaints (e.g., multiple sclerosis), or intellectual disabilities, (5) No diagnosis of substance use disorder - current or in the preceding 1 year as defined by DSM 5, (6) suitable to undergo MRI scan, as per the safety screening questionnaire (not having metal in the body, not being pregnant or suffering from tinnitus).
Patients(1) English or French-speaking, (2) Aged 18-50 years, (3) Patients meeting the DSM 5 criteria for schizophrenia as previously diagnosed by their treating psychiatrist, (4) Patients in a stable phase of the illness (defined as having had no change in Global Functioning of greater than 10 units out of a total range of 100 units for 1 month before the MEG scan), assessed using the Global Assessment of Functioning Scale (Endicott et al, 1976) in the 4 weeks preceding the study, (5) Patients with no diagnosis of substance use disorder - current or in the preceding 1 year as defined by DSM 5 criteria, (6) Patients suitable to undergo MRI scan, as per the safety screening questionnaire (having no metal in the body, not being pregnant or suffering from tinnitus).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Beta-band Oscillatory Power derived from Magnetoencephalography

    The measurement of beta-band oscillatory activity in response to a motor task to assess neurophysiological abnormalities in the temporal regularity of neural activity within the beta-band frequency. These measurements will be obtained using magnetoencephalography (MEG), which captures the oscillatory patterns of brain activity. The focus will be on how these patterns deviate in patients with schizophrenia compared to healthy controls. The primary outcome will assess beta-band power in relation to disorganization in speech.

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2025
  2. Study start8 May 2024
  3. Primary completionNov 2025 (estimated)
  4. Study completionNov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06978881
Sponsor's protocol ID
2024-925
Acronym
MEGPSY
Status last verified
May 2025
First submitted
13 Jan 2025
Last updated
18 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The researchers propose to use a clinical linguistic archiving system called the TalkBank for sharing de-identified speech data (https://www.talkbank.org/). TalkBank registry/database is located at Carnegie Mellon University, Pittsburgh, Pennsylvania-USA. Only the de-deidentified audio (and transcriptions) data will be provided. These are audio files in wave format and text files, with no identifiable patient information or tags. The de-deidentified data will be coded and anonymized before being transferred. Deidentified MEG data will be made available to qualified researchers via the Open MEG Archive (https://omega.bic.mni.mcgill.ca; Dr S. Baillet, co-principal investigator). This repository already contains resting state MEG data from healthy subjects available for re-use and comparative analysis. Open MEG Archive will not be provided with any study participant dataset information.

Questions about this trial

What is this clinical trial studying?

An observational study of Schizophrenia Disorders and Psychosis, run by Douglas Mental Health University Institute at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 18 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Beta-band Oscillatory Power derived from Magnetoencephalography (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in